Validation of a blood test for multi-cancer risk stratification in a lung cancer screening cohort.

ABSTRACT:

Purpose

We report a blinded validation study of a ten-protein marker blood test for assessing risk of developing or harboring nine common cancers in a prospective lung cancer screening cohort.

Patients and methods

The foundation of the multi-cancer risk stratification test (MCaST), test is a 4-marker protein panel consisting of ProSFTPB, CEA, CA125, and CYFRA-21 which has been extensively validated for risk of lung cancer and which has been expanded to include six additional markers to encompass, in addition to lung cancer, prostate, colorectal, breast, ovarian, pancreatic, liver, esophageal, and stomach cancers. Blinded validation samples consisted of 1,235 plasmas collected prior to diagnosis from 171 cancer cases and 526 randomly selected non-case controls. Fixed individu

SUBMITTER: Fahrmann JF 

PROVIDER: S-EPMC12668053 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature